Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Possibilities of using naftidrofuryl in the therapy of cerebrovascular diseases: Literature review and the authors’ observations

https://doi.org/10.14412/2074-2711-2015-4-110-115

Full Text:

Abstract

The efficacy of naftidrofuryl in treating cerebrovascular diseases is analyzed on the basis of a review of the Russian and foreign literature. Naftidrofuryl is a seroton 5-HT2 receptor antagonist and acts on brain energy metabolism mainly during hypoxia or ischemia. The results of preclinical studies proving the antispasmodic and neuroprotective properties of the drug and its capacity to normalize microcirculation in hypoxia are briefly considered. Experimental findings served as a basis for further studies of the efficacy of naftidrofuryl in patients with stroke, chronic cerebral ischemia, or vascular dementia. The use of naftidrofuryl (dusopharm) was demonstrated to statistically significantly enhance the efficiency of rehabilitation in post-stroke patients and to be followed by significant psychoemotional improvement. According to a Cochrane review, the naftidrofuryl-treated patients with vascular dementia showed a tendency towards better executive and cognitive functions, behavior, and mood. The drug was noted to have a positive effect on the health of patients with chronic cerebral ischemia.

The authors provide the data of their trial of naftidrofuryl used in patients with dyscirculatory encephalopathy, which have confirmed its efficacy in this category of patients. The data available in the literature suggest that oral naftidrofuryl has a good tolerability and safety profile in patients with cerebrovascular diseases.

About the Authors

A. N. Belova
Volga Federal Medical Research Centre, Ministry of Health of Russia
Russian Federation
18/1, Verkhne-Volzhskaya Emb., Nizhny Novgorod 603155


D. N. Shakurova
City Clinical Hospital Three
Russian Federation
21, Verkhne-Volzhskaya Emb., Nizhny Novgorod 603155


E. V. Gayazova
City Clinical Hospital Three
Russian Federation
21, Verkhne-Volzhskaya Emb., Nizhny Novgorod 603155


References

1. Парфенов ВА, Хасанова ДР. Ишемический инсульт. Москва: МИА; 2012. 288 с. [Parfenov VA, Khasanova DR. Ishemicheskii insul't [Ischemic stroke]. Moscow: MIA; 2012. 288 p.]

2. Шамалов НА. Реперфузионная терапия при ишемическом инсульте в Российской Федерации: проблемы и перспективы. Неврология, нейропсихиатрия, психосоматика. 2014;6(2S):15-22. [Shamalov NA. Reperfusion therapy for ischemic stroke in the Russian Federation: Problems and promises. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2014;6(2S):15-22. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2014-2S-15-22

3. Maloteaux JM. Biochemical and physiological evidences for antiserotonergic properties of naftidrofuryl. Arzneimittelforschung. 1986 Aug;36(8):1194-8.

4. Davis PTG, Steiner TJ. Effect of naftidrofuryl on human platelet behaviour and evidence for a selective inhibition of 5-HT2 receptors. New Trends Clin Neuropharmacol 1988:111-5.

5. Poncin-Lafitte M, Grosdemouge C, Roy-Billon C, et al. Effects of naftidrofuryl on cerebral hemodynamics. metabolism and function after a retracted ischaemia. Arch Int Pharmacodyn Ther. 1982 Dec;260(2):218-29.

6. Yesavage JA, Tinklenberg JR, Hollister LE, Berger PA. Effect of nafronyl on lactate and pyruvate in the cerebrospinal fluid of patients with senile dementia. J Am Geriatr Soc. 1982

7. Feb;30(2):105-8.

8. Lehert P, Comte S, Gamand S, Brown TM. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol. 1994;23 Suppl 3:S48-52.

9. NICE technology appraisal guidance [TA223]. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Published date: May 2011 http://www.nice.org.uk/guidance/ta223

10. European Stroke Organisation, Tendera M, Aboyans V, Bartelink ML, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011 Nov;32(22):2851-906. doi: 10.1093/eurheartj/ehr211. Epub 2011 Aug 26.

11. Oudart N. Naftidrofuryl inhibits contractions to serotoninin intact and de-endothelialized cerebral arteries in vitro. J Cardiovasc Pharmacol. 1990;16 Suppl 3:S45-8.

12. Wiemsperger N. Serotonin, 5HT receptors and brain circulation. J Cardiovasc Pharmacol. 1990;16 Suppl 3:S20-4.

13. Lagrue G, Questel R. Indirect evaluation of blood oximetry by digitized conjunctival capillarography: effects of naftidrofuryl. J Cardiovasc Pharmacol. 1990;16 Suppl 3:S67-71.

14. Zander JF, Aarhus LL, Katusic ZS, et al. Effects of naftidrofuryl on adrenergic nerves, endothelium and smooth muscle inisolated canine blood vessels. J Pharmacol Exp Ther. 1986 Dec;239(3):760-7.

15. Lepetit J, Dumond D, Gros J. Controle de l'activite du naftidrofuryl a la phase aigue des AVC par I'echopulsographie transcerebrale. Psychol. Med. 1992; 24:975-82.

16. Kirsten R, Erdeg B, Moxter D, et al. Platelet aggregation after naftidrofuryl application in vitro and ex vivo. Int J Clin Pharmacol Ther. 1995 Feb;33(2):81-4.

17. Herrmann KS, Grosse-Heitmeyer A, Kreuzer H. Antithrombotic efficacy and its time course after application of naftidrofuryl in vivo. Arch Int Pharmacodyn Ther. 1986 Nov;284(1):145-54.

18. Takeo S, Tanonaka R, Miyake K, et al. Naftidrofuryl oxalate improves impaired brain glucose metabolism after induced cerebral metabolism in rats. J Pharmacol Exp Ther. 1991 Apr;257(1):404-10.

19. Wiernsperger NF. Serotonin, 5-HT2 receptors, and their blockade by naftidrofuryl: a targeted therapy of vascular disease. J Cardiovasc Pharmacol. 1994;23 Suppl 3:S37-43.

20. Taguchi T, Takagi N, Miyake K, et al. Effects of naftidrofuryl oxalate on microsphereinduced changes in acetylcholine and amino acid content of rat brain regions. Exp Brain Res. 1994;99(1):7-16.

21. Fujikura H, Kato H, Nakano S, Kogure K. Effects of naftidrofuryl oxalate, a 5-HT2 antagonist, on neuronal damage and local cerebral blood flow following transient cerebral ischemia in gerbils. Brain Res. 1989 Aug 14;494(2):387-90.

22. Nabeshima T, Ichihara K, Tohyama K, et al. Involvement of serotonergic neuronal systems in the anti-amnesic action ofnaftidrofuryl oxalate. Eur J Pharmacol. 1991 Nov 19;205(1):55-61.

23. Ogawa S, Kameyama T, Nabeshima T. Naftidrofuryl oxalate, nootropic effects on the scopolamine- and the basal forebrain lesioninduced amnesia in rats. Pharmacol Biochem Behav. 1991 Aug;39(4):997-1002.

24. Louis JC. Effect of naftidrofuryl on metabolism and survival of cultured neurons. Neurochem Res. 1989 Dec;14(12):1195-201.

25. Capon A, Lehert P, Opsomer L. Naftidrofuryl in the treatment of subacute stroke. J Cardiovasc Pharmacol. 1990;16 Suppl 3:S62-6.

26. Admani AK. New approach to treatment of recent stroke. Br Med J. 1978 Dec 16;2(6153):1678-9.

27. Ducarne H. Evaluation of a vasoactive substance, naftidrofuryl. during the rehabilitation phase after an ischemic insult. Curr Med Res Opin. 1986;10(1):58-71.

28. Steiner TJ, Clifford Rose F. Towards a model stroke trial. The single-centre naftidrofuryl study. Neuroepidemiology. 1986;5(3):121-47.

29. Steiner TJ. Naftidrofurilafter acute stroke: a review and a hypotesis. J Cardiovasc Pharmacol. 1990;16 Suppl 3:S58-61.

30. Ковальчук В, Токарева Е. Медикаментозная реабилитация как возможность улучшения функционального состояния пациентов после инсульта. Врач. 2015;(9):52-5. [Koval'chuk V, Tokareva E. Drug rehabilitation as an opportunity to improve the functional status of patients after stroke. Vrach. 2015;(9): 52-5. (In Russ.)].

31. Bouvier B, Passeron O, Chupin M. Psychometric Study of Praxilene. J M Med Res. 1974;2:59-62.

32. Cohn JB, Wilcox CS. Praxilene in the treatment of senile dementia. The International Symposium on Conservative Therapy of Arterial Occlusive Disease. Bonn, Germany, May 25,

33.

34. Grossman WM, Standl A, May U, et al. Naftidrofuryl in the treatment of mild senile dementia. A double-blind study. Pharmacopsychiatry. 1990 Nov;23(6):265-73.

35. Saldmann F, Funel A, Jacquet P. Efficacy of naftidrofuryl in patients with moderate senile dementia. Curr Med Res Opin. 1991; 12(6):379-89.

36. Emeriau JP, Lehert P, Mosnier M. Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results ofa multicenter, double-blind trial. Clin Ther. 2000 Jul;22(7):834-44.

37. Mö ller H, Hartmann A, Kessler C, et al. Naftidrofuryl in the treatment of vascular dementia. Eur Arch Psychiatry Clin Neurosci. 2001 Dec;251(6):247-54.

38. Boeijinga PH, Nedelec JF, Demazieres A, et al. Characterization of the CNS effects of naftidrofuryl (Praxilene) by quantitative EEG and functional MRI: a study in healthy elderly subjects. Neuropsychobiology. 2003;48(3):160-8.

39. Lu D, Song H, Hao Z, et al. Naftidrofuryl for dementia (Review). Cochrane Database Syst Rev. 2011 Dec 7;(12):CD002955. doi: 10.1002/14651858.CD002955.pub4.

40. Kö ltringer P, Langsteger W, Reisecker F, Eber O. Effect of naftidrofuryl on viscoelasticity, thrombocyte aggregation and erythrocyte fluidity of blood. Vasa. 1992;21(4):411-4.

41. Капустин РВ. Влияние препарата Энелбин на нейрогуморальный гомеостаз при дисциркуляторной ангиоэнцефалопатии, обсуловленной гипертонической болезнью. Вестник Харьковского национального университета. 2003;(597):51-2. [Kapustin RV. The influence of Enelbin on neurohumoral homeostasis in the vascular angioencephalopathy, associated with hypertonic disease. Vestnik Khar'kovskogo natsional'nogo universiteta. 2003;(597):51-2. (In Russ.)].

42. Антипенко ЕА. Хроническая ишемия головного мозга (клинико-экспериментальное исследование). Автореф. дисс. докт. мед. наук. Нижний Новгород; 2015. [Antipenko EA. Khronicheskaya ishemiya golovnogo mozga (kliniko-eksperimental'noe issledovanie). Autoref. diss. doct. med. sci. Nizhnii Novgorod; 2015.]

43. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9.

44. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70.

45. Ware J, Sherbourne C. The MOS 36-item short-form health survey (SF-36). Med Care. 1992 Jun;30(6):473-83.

46. De Backer T, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data. BMJ. 2009 Mar 10;338:b603. doi: 10.1136/bmj.b603.

47. Leonardi-Bee J, Steiner T, Bath-Hextall F. Naftidrofuryl for acute stroke. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005478. 46. Legallicier B, Barbier S, Bolloni L, et al. Pharmacokinetics of naftidrofuryl in patients with renal impairment. Arzneimittelforschung. 2005;55(7):370-5.

48. Hulot T, Gamand S, Dupain T, et al. Influence of age on the pharmacokinetics of naftidrofuryl after single oral administration in elderly versus young healthy volunteers. Arzneimittelforschung. 1998 Sep;48(9):900-4.


For citation:


Belova A.N., Shakurova D.N., Gayazova E.V. Possibilities of using naftidrofuryl in the therapy of cerebrovascular diseases: Literature review and the authors’ observations. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(4):110-115. (In Russ.) https://doi.org/10.14412/2074-2711-2015-4-110-115

Views: 461


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)